BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age
This case-control study of US children examines vaccine effectiveness rates of a messenger RNA vaccine during the 2023-2024 respiratory virus season.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Laura Puzniak (ORCID: https://orcid.org/0000-0001-8697-9683)
- Timothy B. Frankland (ORCID: https://orcid.org/0000-0002-0987-8405)
- Vennis Hong (ORCID: https://orcid.org/0000-0002-6060-8419)
- Sara Y. Tartof (ORCID: https://orcid.org/0000-0003-2336-8476)
- Hina Chowdhry
- Brigitte Spence (ORCID: https://orcid.org/0000-0003-2386-9967)
- Jeff Slezak (ORCID: https://orcid.org/0000-0002-6108-9198)
- Julie Stern (ORCID: https://orcid.org/0000-0002-0888-0810)
- Gregg S. Davis (ORCID: https://orcid.org/0000-0001-7684-0426)
- Luis Jódar (ORCID: https://orcid.org/0000-0003-1246-530X)
- John M. McLaughlin
- Joann M. Zamparo
Institutions
- Kaiser Permanente (US)
- Pfizer (United States) (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.49944
- Citations
- 7
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- Pfizer
- Kaiser Permanente